Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.006 AUD 0.00 ( 20.00%)
Last update at 2026-11-06T05:10:00Z
VOLUME
329738
Market Cap
4.93M

Momentum Score

…

Anagenics Limited engages in the health, wellness, and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.00
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Anagenics Ltd (ASX:AN1) is a small-cap Australian listed company; public disclosures give limited detail on its core business activities. Long-term growth may be driven by successful execution of strategic plans, development or commercialisation of any underlying assets, and funding or partner agreements that could support scale.

Key investment risks include scarce public information, execution and financing risk common to small caps, potential regulatory or operational setbacks, and low liquidity that can magnify share volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
5.16M
Revenue Per Share
0.01
Gross Profit TTM
3.00M
Debt / Equity
0.01
ROE
10.19%
Net Debt
-0.54M
ROCE
14.90%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 0.31M -1.24M -7.28M -2.20M -3.64M
Net income 0.31M -1.24M -7.49M -2.67M -3.65M
Selling general administrative - 2.50M 7.87M 4.12M 5.85M
Selling and marketing expenses - 0.45M 2.58M 1.75M 2.38M
Gross profit 2.81M 2.04M 4.36M 4.05M 5.07M
Reconciled depreciation - 0.20M 0.62M 0.36M 0.49M
Ebit 0.63M -1.20M -7.22M -1.92M -2.30M
Ebitda 0.82M -0.99M -6.60M -1.56M -1.80M
Depreciation and amortization 0.19M 0.20M 0.62M 0.36M 0.49M
Operating income 0.63M -1.32M -7.38M -1.92M -2.30M
Other operating expenses 4.53M 6.07M 14.23M 11.03M 13.80M
Interest expense 0.07M 0.04M 0.07M 0.03M 0.07M
Tax provision - 0.00M 0.00M 0.01M 0.00M
Interest income - 0.00M 0.02M 0.02M 0.03M
Net interest income - -0.04M -0.07M -0.01M -0.04M
Extraordinary items - 0.00M -0.21M -0.93M -2.01M
Income tax expense - - 0.21M -0.45M 0.00M
Total revenue 5.16M 4.75M 10.80M 9.11M 9.23M
Total operating expenses 2.18M 3.36M 7.17M 5.97M 9.63M
Cost of revenue 2.35M 2.71M 6.44M 5.06M 4.17M
Total other income expense net -0.32M 0.08M 0.09M -0.28M 0.46M
Discontinued operations - - - -0.93M -2.01M
Net income from continuing ops - -1.24M -7.28M -1.74M -3.65M
Net income applicable to common shares - -1.24M -7.49M -2.67M -3.65M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 4.75M 4.10M 6.45M 11.11M 12.92M
Intangible assets 0.00M 0.00M - 0.00M 0.02M
Other current assets 0.33M - 0.32M 0.05M 0.12M
Total liab 0.52M 2.28M 3.74M 2.22M 4.64M
Total stockholder equity 4.23M 1.83M 2.71M 8.90M 8.29M
Other current liab 0.17M - 0.23M 0.59M 2.25M
Common stock 69.28M - 66.83M 65.36M 62.44M
Capital stock - 67.18M - 65.36M 62.44M
Retained earnings -64.99M -65.30M -64.06M -56.57M -53.90M
Other liab - - - 0.04M 0.12M
Good will 1.95M 1.95M 1.95M 3.45M 3.45M
Other assets - - 0.00M 0.58M -
Cash 0.58M 0.40M 1.62M 2.57M 3.28M
Cash and equivalents - - - 2.57M 3.28M
Total current liabilities 0.52M 2.19M 3.43M 1.71M 3.66M
Current deferred revenue 0.01M - 0.40M - -
Net debt -0.54M 0.15M -0.85M - -1.53M
Short term debt 0.03M - 0.47M 0.00M 0.90M
Short long term debt - 0.54M - - 0.56M
Short long term debt total 0.03M - 0.77M - 1.76M
Other stockholder equity - - -0.00M 0.11M -0.24M
Property plant equipment - - - 0.77M 0.58M
Total current assets 2.74M 1.94M 4.09M 6.25M 8.77M
Net tangible assets - - - 5.38M 4.71M
Net receivables 0.81M 0.63M 0.67M 1.04M 0.92M
Long term debt - - - 0.00M 0.77M
Inventory 1.03M 0.97M 1.48M 2.40M 4.45M
Accounts payable 0.32M 1.06M 2.33M 0.72M 0.50M
Accumulated other comprehensive income -0.07M - -0.06M - -0.24M
Non currrent assets other - - 0.00M 0.58M -
Non current assets total 2.00M 2.16M 2.36M 4.86M 4.15M
Capital lease obligations - 0.31M - 0.65M 0.43M
Long term debt total - - - 0.46M 0.85M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 0.00M -0.20M -1.51M -0.97M
Change to liabilities - - - -0.18M -1.07M
Total cashflows from investing activities -0.02M 0.00M -0.20M -1.51M -0.97M
Net borrowings - 0.54M - -0.34M 0.10M
Total cash from financing activities 1.28M 0.35M 0.99M 2.56M 0.07M
Change to operating activities - - - -0.13M -0.16M
Net income 0.31M -1.24M -7.28M -1.74M -1.64M
Change in cash 0.18M -1.23M -0.94M -0.72M -3.44M
Begin period cash flow 0.40M 1.62M 2.57M 3.28M 6.73M
End period cash flow 0.58M 0.40M 1.62M 2.57M 3.28M
Total cash from operating activities -1.07M -1.58M -1.74M -1.78M -2.55M
Issuance of capital stock - - 1.36M 3.18M -
Depreciation 0.19M - 0.62M 0.36M 0.38M
Other cashflows from investing activities - 0.00M -0.10M -0.62M -0.93M
Dividends paid - - - 0.27M -
Change to inventory -0.06M 0.17M 1.14M 0.04M 0.28M
Change to account receivables -0.23M 0.04M 0.86M -0.05M 1.32M
Sale purchase of stock - 0.00M -0.15M -0.27M 0.00M
Other cashflows from financing activities -0.27M -0.20M -0.03M 0.22M 0.63M
Change to netincome - - - 0.87M 0.26M
Capital expenditures 0.02M 0.00M 0.10M 0.05M 0.04M
Change in working capital -1.56M -0.28M 1.97M -0.32M 0.37M
Stock based compensation - - - 0.02M 0.22M
Other non cash items - -1.29M 2.96M 0.83M -1.43M
Free cash flow -1.09M -1.58M -1.84M -1.83M -2.59M

Peer Comparison*

Sector: Consumer Defensive Industry: Household & Personal Products

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AN1
Anagenics Ltd
0.00
20.00%
0.01 - 4.97 0.95 1.17 1.14 7.77
MCP
Mcphersons Ltd
-
-%
0.13 - 16.08 0.16 0.36 0.17 16.32
S66
Star Combo Pharma Ltd
-0.04
20.00%
0.14 - - 0.80 0.61 0.42 4.45
ZNO
ZOONO Group Ltd
-0.00
5.00%
0.04 - 8.88 9.73 5.76 11.89 -1.38
SKN
Skin Elements Ltd
-
-%
0.00 - - 30.26 8.04 27.95 -0.22

Profile*

Anagenics Ltd

Anagenics Limited engages in the health, wellness, and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

55 Clarence Street, Sydney, NSW, Australia, 2000

61 2 9221 6830

Name Title Year Born
Mr. Matthew Dudek Acting Chief Exec. Officer NA
Mr. Dominic Burg Chief Operating Officer NA
Ms. Carolyn Heath Chief Customer Officer & GM of Sales NA
Dr. Graham Robertson Head of R&D NA
Mr. Scott Mitchell Greasley Exec. Director NA
Mr. Lee Tamplin B.A. Company Sec. NA
Mr. Scott Mitchell Greasley CEO, MD & Executive Director NA
Mr. Matthew Dudek Chief Financial & Governance Officer and Company Secretary NA
Dr. Graham Robertson Head of Research & Development NA
Mr. Scott Mitchell Greasley CEO, MD & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…